dc.contributor.author | Sánchez Botet, Abril | |
dc.contributor.author | Gasa Colom, Laura | |
dc.contributor.author | Quandt Herrera, Eva | |
dc.contributor.author | Hernández Ortega, Sara | |
dc.contributor.author | Jiménez Jiménez, Javier | |
dc.contributor.author | Mezquita Mas, Pau | |
dc.contributor.author | Carrasco García, Miguel Ángel | |
dc.contributor.author | Kron, Stephen J. | |
dc.contributor.author | Vidal, August | |
dc.contributor.author | Villanueva, Alberto | |
dc.contributor.author | P.C. Ribeiro, Mariana | |
dc.contributor.author | Clotet Erra, Josep | |
dc.date.accessioned | 2019-10-13T14:13:53Z | |
dc.date.available | 2019-10-13T14:13:53Z | |
dc.date.issued | 2018-08-07 | |
dc.identifier.citation | Sánchez-Botet, A., Gasa, L., Quandt, E., Hernández-Ortega, S., Jiménez, J., Mezquita, P., Carrasco García, M.A., J. Kron, Stephen, Vidal, August, Villanueva, Alberto, Ribeiro, M. P. & Clotet, Josep (2018). «The atypical cyclin CNTD2 promotes colon cancer cell proliferation and migration». Scientific reports, 8(1), 11797. | ca |
dc.identifier.issn | 2045-2322 | ca |
dc.identifier.uri | http://hdl.handle.net/20.500.12328/1256 | |
dc.description.abstract | Colorectal cancer (CRC) is one of the most common cancers worldwide, with 8–10% of these tumours presenting a BRAF (V600E) mutation. Cyclins are known oncogenes deregulated in many cancers, but the role of the new subfamily of atypical cyclins remains elusive. Here we have performed a systematic analysis of the protein expression levels of eight atypical cyclins in human CRC tumours and several cell lines, and found that CNTD2 is significantly upregulated in CRC tissue compared to the adjacent normal one. CNTD2 overexpression in CRC cell lines increases their proliferation capacity and migration, as well as spheroid formation capacity and anchorage-independent growth. Moreover, CNTD2 increases tumour growth in vivo on xenograft models of CRC with wild-type BRAF. Accordingly, CNTD2 downregulation significantly diminished the proliferation of wild-type BRAF CRC cells, suggesting that CNTD2 may represent a new prognostic factor and a promising drug target in the management of CRC. | ca |
dc.format.extent | 12 | ca |
dc.language.iso | eng | ca |
dc.publisher | Scientific Reports | |
dc.rights | https://creativecommons.org/licenses/by/4.0/ | ca |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject.other | colon cancer | ca |
dc.subject.other | cáncer de colon | ca |
dc.subject.other | càncer de colon | ca |
dc.subject.other | CNTD2 | ca |
dc.subject.other | tumours | ca |
dc.subject.other | tumores | ca |
dc.subject.other | tumors | ca |
dc.title | The atypical cyclin CNTD2 promotes colon cancer cell proliferation and migration | ca |
dc.type | info:eu-repo/semantics/article | ca |
dc.description.version | info:eu-repo/semantics/acceptedVersion | ca |
dc.embargo.terms | cap | ca |
dc.subject.udc | 616.3 | ca |
dc.identifier.doi | 10.1038/s41598-018-30307-x | ca |